# Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

> **NCT03898908** · PHASE2 · COMPLETED · sponsor: **Grupo Español Multidisciplinar de Melanoma** · enrollment: 48 (actual)

## Conditions studied

- Metastatic Melanoma
- Brain Metastases

## Interventions

- **DRUG:** encorafenib
- **DRUG:** binimetinib
- **RADIATION:** Whole brain radiation therapy
- **RADIATION:** Radiosurgery/stereotactic radiosurgery

## Key facts

- **NCT ID:** NCT03898908
- **Lead sponsor:** Grupo Español Multidisciplinar de Melanoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-18
- **Primary completion:** 2022-10-10
- **Final completion:** 2023-07-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03898908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03898908, "Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03898908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*